Healthcare provider profile · identity verified

Gary M. Clay, M.D.

Family Practice · MIAMI, FL · NPI 1548705239

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	402	108
Eliquis	Apixaban	319	53
Gabapentin	Gabapentin	283	73
Amlodipine Besylate	Amlodipine Besylate	250	59
Metoprolol Tartrate	Metoprolol Tartrate	216	58
Nystatin	Nystatin	202	34
Tamsulosin Hcl	Tamsulosin Hcl	146	34
Pantoprazole Sodium	Pantoprazole Sodium	138	35
Levetiracetam	Levetiracetam	137	37
Metformin Hcl	Metformin Hcl	137	37
Furosemide	Furosemide	129	33
Clopidogrel	Clopidogrel Bisulfate	125	35
Levothyroxine Sodium	Levothyroxine Sodium	123	32
Carvedilol	Carvedilol	118	35
Hydralazine Hcl	Hydralazine Hcl	116	31
Losartan Potassium	Losartan Potassium	114	27
Lisinopril	Lisinopril	112	31
Quetiapine Fumarate	Quetiapine Fumarate	107	28
Metoprolol Succinate	Metoprolol Succinate	101	22
Trazodone Hcl	Trazodone Hcl	99	29
Insulin Lispro Kwikpen U-100	Insulin Lispro	95	24
Potassium Chloride	Potassium Chloride	95	34
Escitalopram Oxalate	Escitalopram Oxalate	85	17
Midodrine Hcl	Midodrine Hcl	83	17
Donepezil Hcl	Donepezil Hcl	81	23
Lactulose	Lactulose	78	19
Famotidine	Famotidine	76	24
Duloxetine Hcl	Duloxetine Hcl	73	15
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	69	37
Memantine Hcl	Memantine Hcl	69	15
Trulicity	Dulaglutide	68	11
Nifedipine Er	Nifedipine	66	24
Sertraline Hcl	Sertraline Hcl	61	18
Xarelto	Rivaroxaban	59	11
Divalproex Sodium	Divalproex Sodium	58	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	57	20
Januvia	Sitagliptin Phosphate	57	suppressed
Levofloxacin	Levofloxacin	57	37
Finasteride	Finasteride	54	13
Mirtazapine	Mirtazapine	54	18
Rosuvastatin Calcium	Rosuvastatin Calcium	54	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	52	13
Latanoprost	Latanoprost	42	11
Omeprazole	Omeprazole	42	11
Baclofen	Baclofen	39	12
Allopurinol	Allopurinol	36	12
Clonidine Hcl	Clonidine Hcl	35	suppressed
Glipizide	Glipizide	35	suppressed
Humalog Kwikpen U-100	Insulin Lispro	34	suppressed
Ondansetron Hcl	Ondansetron Hcl	34	22
Carbidopa-Levodopa	Carbidopa/Levodopa	33	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	33	19
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	32	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	32	17
Mupirocin	Mupirocin	32	23
Prednisone	Prednisone	32	11
Amiodarone Hcl	Amiodarone Hcl	31	suppressed
Silodosin	Silodosin	31	suppressed
Sodium Chloride	0.9 % Sodium Chloride	31	16
Lorazepam	Lorazepam	30	suppressed
Jardiance	Empagliflozin	29	suppressed
Bumetanide	Bumetanide	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	19
Buspirone Hcl	Buspirone Hcl	27	11
Cephalexin	Cephalexin	27	16
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	27	15
Vancomycin Hcl	Vancomycin/Water For Inj (Peg)	27	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	25	suppressed
Insulin Lispro	Insulin Lispro	24	12
Montelukast Sodium	Montelukast Sodium	24	suppressed
Benztropine Mesylate	Benztropine Mesylate	23	suppressed
Ceftriaxone	Ceftriaxone Sodium	23	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	23	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	11
Hydrochlorothiazide	Hydrochlorothiazide	22	suppressed
Simvastatin	Simvastatin	22	14
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Alendronate Sodium	Alendronate Sodium	21	suppressed
Azithromycin	Azithromycin	21	12
Atenolol	Atenolol	20	suppressed
Albuterol Sulfate	Albuterol Sulfate	19	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Risperidone	Risperidone	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	16
Divalproex Sodium Er	Divalproex Sodium	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Brilinta	Ticagrelor	17	suppressed
Clonidine	Clonidine	17	suppressed
Diltiazem Hcl	Diltiazem Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Amantadine	Amantadine Hcl	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Rezvoglar Kwikpen	Insulin Glargine-Aglr	16	suppressed
Thalitone	Chlorthalidone	16	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Lamotrigine	Lamotrigine	15	suppressed
Ertapenem	Ertapenem Sodium	13	suppressed
Metformin Hcl Er	Metformin Hcl	13	suppressed
Methimazole	Methimazole	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Retacrit	Epoetin Alfa-Epbx	13	suppressed
Zenpep	Lipase/Protease/Amylase	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Procrit	Epoetin Alfa	12	suppressed
Valsartan	Valsartan	12	suppressed
Calcitriol	Calcitriol	11	suppressed
Calcium Acetate	Calcium Acetate	11	suppressed
Cefdinir	Cefdinir	11	suppressed
Entresto	Sacubitril/Valsartan	11	suppressed
Insulin Aspart	Insulin Aspart	11	suppressed
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Torsemide	Torsemide	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Zonisamide	Zonisamide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error